Vertaling van "securities laws and shareholder " (Nederlands → Frans) :

Chiron/Fluvirin The former Chiron Corporation, which Novartis acquired during 2006, was the subject of a number of legal proceedings arising out of Chiron’s inability to deliver its Fluvirin influenza vaccine to the US market for the 2004/05 flu season, including class-action lawsuits alleging breaches of securities laws and shareholder derivative lawsuits alleging breaches of fiduciary duties.
Fluvirin de Chiron L’ancien groupe Chiron Corporation, racheté par Novartis au cours de 2006, faisait l’objet de plusieurs actions en justice en rapport avec son incapacité à fournir le vaccin anti-grippe Fluvirin sur le marché américain pour la saison grippale 2004/05.

Acquisitions of subsidiaries -26 666 -890 -25 776 Change in marketable securities 12 821 -7 508 20 329 Cash flow used for investing activities -15 169 -10 026 -5 143 Change in current and non-current financial debts 12 258 6 810 5 448 Dividends paid to shareholders of Novartis AG -4 486 -3 941 -545 Treasury share transactions 438 80 358 Other financing cash flows -34 1 -35 Cash flow from financing activities 8 176 2 950 5 226 Translation effect on cash and cash equivalents -5 86 -91 Change in cash and cash equivalents 2 492 735 1 757 Cash and cash equivalents at January 1 2 894 2 038 856 Cash and cash equivalents at September 30 5 386 2 773 2 613
Acquisitions de filiales -26 666 -890 -25 776 Variation des titres de placement 12 821 -7 508 20 329 Flux de trésorerie des activités d’investissement -15 169 -10 026 -5 143 Variation des dettes financières à court et long terme 12 258 6 810 5 448 Dividendes versés aux actionnaires de Novartis AG -4 486 -3 941 -545 Transactions sur actions propres 438 80 358 Autres flux de financement -34 1 -35 Flux de trésorerie des activités de financement 8 176 2 950 5 226 Effet nets des écarts de conversion sur la trésorerie et les équivalents de trésorerie -5 86 -91

The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.
The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.